# Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

> **NCT04728646** · PHASE4 · WITHDRAWN · sponsor: **Massachusetts Eye and Ear Infirmary**

## Conditions studied

- Graft Vs Host Disease

## Interventions

- **DRUG:** DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
- **DEVICE:** Regular dissolvable intracanalicular plug

## Key facts

- **NCT ID:** NCT04728646
- **Lead sponsor:** Massachusetts Eye and Ear Infirmary
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09
- **Primary completion:** 2021-12-13
- **Final completion:** 2021-12-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to difficulty enrolling subjects whom had not meet the inclusion criteria
- **Last updated:** 2022-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728646, "Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04728646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*